

# Rafael Banares

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6156870/publications.pdf>

Version: 2024-02-01

86  
papers

8,398  
citations

50276

46  
h-index

51608

86  
g-index

94  
all docs

94  
docs citations

94  
times ranked

5428  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2022, 45, 724-734.	0.5	3
2	Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature. <i>Hepatology Communications</i> , 2021, 5, 309-322.	4.3	13
3	A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e587-e593.	1.6	1
4	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	3.7	28
5	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100368.	4.9	3
6	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 313-327.e6.	4.4	74
7	Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?" <i>Journal of Hepatology</i> , 2020, 73, 977-979.	3.7	0
8	Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis. <i>Clinical Infectious Diseases</i> , 2020, 71, 2726-2729.	5.8	23
9	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2020, 73, 1415-1424.	3.7	104
10	Intraoperative Troponin Elevation in Liver Transplantation Is Independently Associated With Mortality: A Prospective Observational Study. <i>Liver Transplantation</i> , 2020, 26, 681-692.	2.4	3
11	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	3.7	112
12	Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. <i>Journal of Hepatology</i> , 2020, 73, 1404-1414.	3.7	58
13	β-blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet</i> , 2019, 393, 1597-1608.	13.7	375
14	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. <i>Gastroenterología Y Hepatología</i> (English Edition), 2019, 42, 657-676.	0.1	1
15	It takes two "eyes" to see in depth. <i>Journal of Hepatology</i> , 2019, 70, 790-791.	3.7	1
16	Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 657-676.	0.5	12
17	Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis. <i>BMC Infectious Diseases</i> , 2018, 18, 170.	2.9	2
18	Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis. <i>Hepatology</i> , 2017, 65, 2019-2030.	7.3	43

#	ARTICLE	IF	CITATIONS
19	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2017, 40, 538-580.	0.1	10
20	Effects of All-Oral Anti-Viral Therapy on HVPG and SystemicÃHemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. <i>Gastroenterology</i> , 2017, 153, 1273-1283.e1.	1.3	210
21	Enfermedades vasculares del hÃgado. GuÃas ClÃnicas de la Sociedad Catalana de DigestologÃa y de la AsociaciÃ³n EspaÃola para el Estudio del HÃgado. <i>GastroenterologÃa Y HepatologÃa</i> , 2017, 40, 538-580.	0.5	20
22	De novo autoimmune hepatitis after liver transplantation: A focus on glutathione SÃ-transferase theta 1. <i>Liver Transplantation</i> , 2017, 23, 75-85.	2.4	7
23	Development of hyperdynamic circulation and response to Î²-blockers in compensated cirrhosis with portal hypertension. <i>Hepatology</i> , 2016, 63, 197-206.	7.3	143
24	Early Measurement of Indocyanine Green Clearance Accurately Predicts Short-Term Outcomes After Liver Transplantation. <i>Transplantation</i> , 2016, 100, 613-620.	1.0	24
25	Liver Support With Albumin Dialysis Reduces Hepatitis C Virus Viremia and Facilitates Antiviral Treatment of Severe Hepatitis C Virus Recurrence After Liver Transplantation. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 189-196.	0.9	1
26	Extravascular Lung Water and Pulmonary Vascular Permeability Index Measured at the End of Surgery Are Independent Predictors of Prolonged Mechanical Ventilation in Patients Undergoing Liver Transplantation. <i>Anesthesia and Analgesia</i> , 2015, 121, 736-745.	2.2	25
27	Impact of anticoagulation on upperÃgastrointestinal bleeding in cirrhosis. A retrospective multicenter study. <i>Hepatology</i> , 2015, 62, 575-583.	7.3	105
28	Effect of Eradication of HCV on Hepatic Venous Pressure Gradient in HIV-Infected Patients With Compensated HCV-Related Cirrhosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, e142-e144.	2.1	3
29	Current Clinical Status of the Extracorporeal Liver Support Devices. , 2015, , 1463-1487.		4
30	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1846-1853.e1.	4.4	60
31	Characteristic haemodynamic changes of cirrhosis may influence the diagnosis of portopulmonary hypertension. <i>Liver International</i> , 2015, 35, 353-361.	3.9	11
32	Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. <i>World Journal of Transplantation</i> , 2014, 4, 133.	1.6	18
33	Oral probiotic <sc>VSL</sc>#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. <i>Liver International</i> , 2014, 34, 1504-1512.	3.9	61
34	Molecular Adsorbent Recirculating System and Bioartificial Devices for Liver Failure. <i>Clinics in Liver Disease</i> , 2014, 18, 945-956.	2.1	24
35	A Histologic Scoring System for Prognosis of Patients With AlcoholicÃHepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6.	1.3	353
36	Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 334-343.	1.5	22

#	ARTICLE	IF	CITATIONS
37	Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 487-495.	1.5	38
38	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. <i>Hepatology</i> , 2013, 57, 1153-1162.	7.3	452
39	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. <i>Hepatology</i> , 2013, 58, 2079-2088.	7.3	48
40	Serum level of soluble vascular cell adhesion molecule in patients with hepatocellular carcinoma and its association with severity of liver disease. <i>Annals of Hepatology</i> , 2013, 12, 236-247.	1.5	3
41	Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 204-211.	1.5	29
42	Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 776-783.	4.4	407
43	The heart in liver transplantation. <i>Journal of Hepatology</i> , 2011, 54, 810-822.	3.7	84
44	Prognostic Markers in Patients Who Have Recovered from an Acute Variceal Bleeding: Role of HVPG Measurement. <i>Disease Markers</i> , 2011, 31, 165-169.	1.3	3
45	Extracorporeal Artificial Liver Support Systems. , 2011, , 501-519.		1
46	Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. <i>Liver International</i> , 2010, 30, 1137-1142.	3.9	87
47	Risk factors for developing <i>de novo</i> autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 530-539.	2.4	52
48	Early noninvasive measurement of the indocyanine green plasma disappearance rate accurately predicts early graft dysfunction and mortality after deceased donor liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 1247-1253.	2.4	46
49	Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2009, 136, 1651-1658.	1.3	372
50	Serum levels of soluble vascular cell adhesion molecule are related to hyperdynamic circulation in patients with liver cirrhosis. <i>Liver International</i> , 2008, 28, 1129-1135.	3.9	16
51	A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 2747-2756.	0.4	268
52	Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. <i>Journal of Hepatology</i> , 2008, 48, 229-236.	3.7	284
53	Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1412-1417.	4.4	175
54	Meta-analysis: Combination Endoscopic and Drug Therapy to Prevent Variceal Rebleeding in Cirrhosis. <i>Annals of Internal Medicine</i> , 2008, 149, 109.	3.9	169

#	ARTICLE	IF	CITATIONS
55	Cardiac Dysfunction During Liver Transplantation: Incidence and Preoperative Predictors. <i>Transplantation</i> , 2008, 85, 1766-1772.	1.0	77
56	Value of the Hepatic Venous Pressure Gradient to Monitor Drug Therapy for Portal Hypertension: A Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2007, 102, 1116-1126.	0.4	137
57	The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis. <i>Gut</i> , 2007, 56, 259-264.	12.1	24
58	Antibodies Against Glutathione S-Transferase T1 (GSTT1) in Patients With GSTT1 Null Genotype as Prognostic Marker: Long-Term Follow-Up After Liver Transplantation. <i>Transplantation</i> , 2007, 83, 1126-1129.	1.0	38
59	Use of Everolimus as a Rescue Immunosuppressive Therapy in Liver Transplant Patients With Neoplasms. <i>Transplantation</i> , 2007, 84, 786-791.	1.0	48
60	Prevalence of portal hypertensive duodenopathy in cirrhosis: clinical and haemodynamic features. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 649-653.	1.6	35
61	Does interferon improve portal hypertension?. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 7-12.	3.0	3
62	Antiviral Therapy Decreases Hepatic Venous Pressure Gradient in Patients with Chronic Hepatitis C and Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2006, 101, 2269-2274.	0.4	150
63	Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma. <i>Hepatology</i> , 2005, 41, 566-571.	7.3	32
64	Reply:. <i>Hepatology</i> , 2005, 42, 236-237.	7.3	1
65	Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. <i>Hepatology</i> , 2005, 42, 793-801.	7.3	213
66	A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. <i>Journal of Hepatology</i> , 2005, 43, 990-996.	3.7	151
67	Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. <i>European Journal of Radiology</i> , 2005, 55, 120-124.	2.6	95
68	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT. <i>Hepatology</i> , 2003, 37, 1260-1266.	7.3	149
69	Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. <i>Liver International</i> , 2003, 23, 39-43.	3.9	85
70	Response to steroids in <i>de novo</i> autoimmune hepatitis after liver transplantation. <i>Hepatology</i> , 2002, 35, 349-356.	7.3	164
71	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002, 36, 1367-1373.	7.3	121
72	TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial. <i>Hepatology</i> , 2002, 35, 385-392.	7.3	195

#	ARTICLE	IF	CITATIONS
73	Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysis. <i>Hepatology</i> , 2002, 35, 609-615.	7.3	401
74	Reply:. <i>Hepatology</i> , 2002, 36, 1024-1025.	7.3	0
75	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002, 36, 1367-1373.	7.3	113
76	Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. <i>Gastroenterology</i> , 2001, 121, 382-388.	1.3	159
77	Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. <i>Journal of Hepatology</i> , 2001, 35, 712-718.	3.7	135
78	Randomized Controlled Trial of Aspiration Needle versus Automated Biopsy Device for Transjugular Liver Biopsy. <i>Journal of Vascular and Interventional Radiology</i> , 2001, 12, 583-587.	0.5	40
79	Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study. <i>Hepatology</i> , 2000, 32, 471-476.	7.3	196
80	Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha<sub>1</sub>-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. <i>Hepatology</i> , 1999, 30, 79-83.	7.3	158
81	Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings. <i>Gastroenterology</i> , 1998, 114, 1296-1303.	1.3	431
82	Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis. <i>Journal of Hepatology</i> , 1998, 29, 779-788.	3.7	94
83	Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. <i>Hepatology</i> , 1995, 21, 674-679.	7.3	171
84	Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function. <i>Gastroenterology</i> , 1995, 109, 1257-1265.	1.3	130
85	Hemodynamic effects of Î±-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. <i>Hepatology</i> , 1994, 20, 611-617.	7.3	64
86	Oral administration of clonidine in patients with alcoholic cirrhosis. <i>Gastroenterology</i> , 1992, 102, 248-254.	1.3	57